Unlocking uterine biology at home: a validated system for DNA, RNA, and microbial analysis from menstrual effluence

Stephen Gire[1], *Xitong Li*[1], *Claire Toth*[1], *Meet Doshi*[3], *Sachin Kumar Gupta*[3], *Scott Parker*[2], *Debbie Boles*[2], *Ridhi Tariyal*[1]

1. NextGen Jane, Inc. Oakland, California
2. Labcorp, Research Triangle Park, North Carolina
3. Elucidata, San Francisco, California

Corresponding Authors:

Stephen Gire: stephen@nextgenjane.com

Ridhi Tariyal: ridhi@nextgenjane.com

ABSTRACT

Introduction: Access to accurate, non-invasive diagnostics remains a critical unmet need in women's health. Menstrual effluence, containing endometrial tissue, immune cells, and microbial communities, represents a clinically relevant specimen for genomic and molecular pathology applications, yet has historically been underutilized due to concerns about sample integrity and variability.

Methods: We developed and validated a standardized, at-home tampon-based collection system designed to preserve nucleic acids at ambient temperature for clinical-grade analyses. 1,067 tampon samples from 328 participants underwent, exome sequencing, RNA sequencing, and metatranscriptomic profiling to assess specimen transcript integrity, diagnostic fidelity, and microbial composition over time.

Results: RNA extracted from menstrual effluence maintained stability for up to 14 days without refrigeration, achieving sufficient yield and quality for sequencing in >97% of samples. Variant detection via exome sequencing demonstrated 100% concordance among overlapping single nucleotide variants between menstrual fluid and matched venous blood, confirming clinical equivalency for genetic testing. Transcriptomic analyses revealed cycle-dependent variation in key reproductive and immune markers, while metatranscriptomic profiling identified shifts in microbial communities consistent with known reproductive tract dysbiosis.

Conclusions: Standardized at-home collection of menstrual effluence provides a clinically actionable platform that supports remote specimen acquisition without compromising molecular assay fidelity, offering a scalable solution to improve access to carrier screening, reproductive health assessment, and infectious disease monitoring in clinical practice.

INTRODUCTION

Women's health has been underserved by non-specific diagnostics and limited therapeutic options. Despite high disease burden, conditions like endometriosis, fibroids, and recurrent

39 miscarriage are diagnosed and treated with tools that lack precision, leading to significant delays
40 in care[1]. Broader reliance on non-specific clinical pathways has led to a one-size-fits-all approach
41 to care[2–4]. For instance, gonadotropin-releasing hormone (GnRH) analogs—despite inducing
42 premature menopause and causing severe side effects such as bone loss and mood
43 disturbances[5] – remain a first-line treatment for endometriosis[6] and fibroid-related heavy
44 bleeding[7]. CA125, a non-specific marker of inflammation, is monitored across a wide range of
45 conditions including ovarian cancer[8], heart failure[9], miscarriage risk[10], and endometriosis[11],
46 despite limited diagnostic specificity[12]. Without condition-specific diagnostics, targeted therapies
47 have remained underdeveloped, perpetuating inadequate care across puberty, pregnancy, and
48 menopause.
49
50 At-home biospecimen collection systems offer a scalable way to improve diagnostics and enable
51 precision medicine in women's health. Remote collection of biological samples allows clinical data
52 to be captured outside of brick-and-mortar healthcare settings, improving access and enabling
53 earlier decision-making[13]. For research, these systems offer opportunities to build rich,
54 longitudinal, high-dimensional datasets that are essential for studying reproductive biology at
55 scale. However, few such datasets exist, and those available are poorly harmonized[14], limiting
56 their cross-study comparability and value for biomarker discovery.
57
58 Menstrual effluence is a rich but underutilized biospecimen that closely mirrors the endometrial
59 environment and presents novel opportunities for diagnostic development. Menstrual fluid is
60 expelled naturally and contains a mix of shed endometrium, interstitial fluid, blood, mucosa, and
61 epithelial cells from the cervix and vagina, along with reproductive tract microbiota[15,16]. Organoids
62 derived from menstrual effluence demonstrate similar transcriptomic profiles and hormone
63 responsiveness as those from invasive endometrial biopsies[17]. Importantly, menstrual effluence
64 contains a unique population of immune cells enriched for innate and adaptive subsets involved

65 in tissue remodeling and immune tolerance[18], unlike peripheral blood. The sample's heterogeneity
66 captures a broader snapshot of uterine and vaginal health than traditional biopsies or swabs.
67 Despite its promise, menstrual effluence has historically been viewed as technically difficult to
68 work with. Approximately 30% of cells in menstrual fluid are non-viable[15,16], and tissue aggregates
69 and mucosal debris complicate laboratory workflows. Additionally, cellular lysis releases
70 nucleases that can degrade nucleic acids, compromising downstream molecular assays. Sample
71 composition also varies by collection method[19] – e.g., pad vs. tampon vs. menstrual cup –
72 introducing variability and contributing to skepticism about its reliability as a biospecimen.
73 However, these challenges are surmountable with proper pre-analytical protocols.
74
75 New advances have transformed how menstrual effluence is viewed in diagnostics and research.
76 Recent studies have generated high-resolution datasets from menstrual fluid and uterine tissue
77 that offer insight into reproductive pathophysiology[15,16,20]. Transcriptomic data from menstrual
78 effluence have revealed dynamic biological processes such as epithelial-to-mesenchymal
79 transition relevant to endometriosis progression[21]. Endotoxins detected in menstrual samples
80 have been linked to adverse pregnancy outcomes[22], and menstrual immune profiles have shown
81 potential for diagnosing inflammatory and infectious conditions[23]. These discoveries demonstrate
82 that menstrual effluence is not only clinically relevant but may offer information inaccessible via
83 other sample types.
84
85 We developed a standardized, tampon-based system to enable high-quality menstrual fluid
86 collection at home. To address pre-analytical variability and improve sample stability, we built a
87 self-contained tampon collection kit that also captures metadata such as cycle day and bleeding
88 volume, which serve as important co-variables in transcriptomic analyses. Prior research has
89 shown that aligning sample timing with menstrual phase improves diagnostic accuracy in
90 cardiovascular[24] and mental health applications[25]. The NextGen Jane® (NGJ) platform enables

91 consistent sample collection, better supports hormonal context interpretation, and allows for
92 widespread use in both clinical and research settings.
93
94 We validated our tampon-based sample collection system through large-scale deployment and
95 demonstrated its feasibility and diagnostic utility in three clinically relevant applications through
96 DNA exome sequencing (carrier screening) and unbiased RNA sequencing of human and
97 microbial cell types (molecular phenotyping and microbial surveillance). We have collected 2,025
98 RNA-seq and metatranscriptomic datasets from 1,067 tampons submitted by 328 U.S.
99 participants. All samples were home-collected and shipped at ambient temperature to a
100 centralized lab in Oakland, CA, without loss of data quality – demonstrating the viability of
101 decentralized sampling for molecular diagnostics.
102
103 **MATERIALS AND METHODS**
104 A thorough accounting of materials and methods can be found in Supplemental Methods.docx
105
106 **Patient Recruitment and Metadata Collection**
107 Patients were recruited under IRB-approved protocols (20192619, 20191947, 20233438).
108 Consent was obtained from participants who agreed to tampon-based specimen collection and
109 completed a survey on clinical history, menstrual regimen, and demographics. Data were
110 organized in four tiers: patient-level (race, ethnicity), cycle-level (age, geography, birth control),
111 tampon/kit-level (flow type, cycle day), and sample-level (RNA concentration, library size).
112 Sample accession and collection dates were recorded to assess sample stability over time. Flow
113 rate was calculated from the weight of the tampon before and after collection. Metadata can be
114 found in Supplemental_RNASeq.xlsx. Patient IDs C01-, H01, E01), Kit IDs (NAPS) and Sample
115 IDs (ESGs), are randomized and anonymized ID's that cannot be tied back to patients outside
116 the research team.

117

118 **Sample Collection and Processing**

119 Participants used organic cotton tampons during multiple days of menstruation, wearing them for
120 4 hours. After collection, the tampon was sealed in a collection jar with 20mL of preservation
121 buffer (Norgen Biotek). Samples were sent back to the lab via USPS. Upon receipt, samples were
122 processed, including extrusion, centrifugation, and aliquoting into cryovials for storage at -80°C.

123

124 **Hemoglobin Content Spectrophotometry**

125 The tampon sample was diluted 1:4 with a preservation buffer and analyzed using a UV/Vis
126 spectrophotometer to measure absorbance at 550nm.

127

128 **Nucleic Acid Extraction and Quality Assessment**

129 RNA and DNA were extracted using the Norgen Column-Based RNA Extraction and MagMax
130 mirVana Total RNA Isolation methods. For RNA, DNase treatment was applied, followed by clean-
131 up with RNA XP clean beads. DNA was extracted using the MagMax-96 DNA Multi-Sample Kit.
132 The extracted nucleic acids were quantified using a Qubit 4.0 fluorometer.

133

134 **Exome Sequencing and Carrier Screening**

135 DNA exome sequencing was outsourced to Labcorp for analysis under their established
136 protocols. SNVs and sample metadata can be found in Supplemental_DNASeq.xlsx

137

138 **RNA Sequencing and Analysis**

139 RNA libraries were prepared using the Zymo-Seq RiboFree Total RNA Library Kit, followed by
140 sequencing on an Illumina NextSeq2000. Data processing included adapter trimming, alignment
141 to the hg38 human genome, and gene count normalization using STAR Aligner and
142 FeatureCount. RNA degradation effects were accounted for using the DegNorm program.

143 Sequencing metadata and gene expression values can be found in Supplemental_RNASeq.xlsx.
144 Tampon and menstrual cup samples were compared to publicly available RNA sequencing data
145 on GTeX to calculate Spearman correlations between tissue types. Samples used for this analysis
146 can be found in Supplemental_GTeX.xlsx. Differential expression was performed in XLSTAT.
147

148 **Microbiome Analysis**

149 Metatranscriptomic reads were aligned to microbial databases using Kraken2 to generate raw
150 read counts. For microbiome diversity, species-level and genus-level counts were aggregated to
151 genus level and analyzed using log-transformation and CPM normalization. Sequencing
152 metadata and gene expression values can be found in Supplemental_RNASeq.xlsx
153

154 **Metadata and Statistical Analysis**

155 Metadata, including clinical phenotypes and sample characteristics, were used in ANOVA to
156 assess statistical significance across various groups. Both pvalue and cohen's f for effect size
157 were calculated for all analyses using XLSTAT. Analysis focused on bleeding phenotypes, flow
158 rates, and other collection-related variables.
159

160 **RESULTS**

161 **A tampon-based at-home collection system can reproducibly collect menstrual effluence**
162 **for downstream molecular analyses under real-world mailing and storage conditions.**

163 The NGJ tampon collection system was designed for ease-of-use, integration into daily routines,
164 and standardization to ensure reliable biological preservation. Participants use the provided
165 TOTM-brand organic, low-absorbency tampons, minimizing synthetic additives and heavy metals.
166 Tampons are worn for four hours – reducing toxic shock risk and facilitates sample processing.
167 The cardboard applicator reduces contact with the absorbent core, limiting commensal
168 contamination. A nitrile glove is included for removal and placement into the jar. Once sealed, the

169 cap pulls the string into the jar, preventing leaks, and a shuttle punctures a foil seal to release the
170 preservation buffer, supersaturating the tampon. The sample is bagged, intake questions
171 completed and returned via standard mail. User-tested instructions guide participants through the
172 collection process. A picture of the collection kit and cover of the instructions for use can be found
173 in Figure 1.
174
175 *Demographic Data of Sample Population* – We analyzed menstrual samples collected on cycle
176 days 1–3 with complete phenotypic and technical data (Supplementary Table 1). Inclusion criteria
177 ensured samples were menstrual (not off-cycle vaginal tampons), had complete metadata (flow
178 type, collection time, bleeding phenotype), and passed sequencing quality checks (strandedness,
179 ribosomal rRNA content and uniquely mapped reads). This resulted in 1,135 sequences from 601
180 tampons across 276 participants.
181
182 Table 1 summarizes participant demographics and key flow characteristics. 75% (207
183 participants) identified as Non-Hispanic White, with the remaining 69 participants identifying as
184 Asian, Black, or more than one race. Of 365 cycles, 287 were from individuals not using birth
185 control. Enrolled participants were asked to report the ***flow phenotype*** (overall period heaviness),
186 characterized as heavy, medium or light, corresponding to their subjective experience of their
187 entire menstrual cycle at the time of collection. ***Flow type*** (heaviness on the collection day) was
188 also reported by participants. These measures differ – e.g., a heavy-flow tampon from a light
189 bleeder may differ significantly from one of a heavy bleeder.
190
191 ***Menstrual effluence preserved in stabilization buffer maintains sufficient RNA integrity for***
192 ***sequencing for at least 14 days at ambient temperature.***
193 Home-based sample collection enables large-scale, longitudinal studies across diverse locations.
194 We report nucleic acid yields from our tampon collection system and transcript degradation index

195 (DI), similar to the transcript integrity number (TIN)[26,27]. For sequencing, 11% of samples failed at
196 least once. Among initially failed samples, 79% were successfully resequenced, yielding a final
197 estimated sample failure rate of 2.3%. Approximately 60 million reads are generated per sample
198 (median = 60 million ± 23 million reads), which include both human and microbial transcripts.
199 Nucleic acid extracted from a 600ul aliquot of sample yields enough RNA for downstream
200 sequencing. After lysate release from tampons, an average of 17 mL of total volume
201 (mean = 17.13 ± 2.73) was recovered, providing sufficient material for downstream assays. A
202 500 ng RNA threshold – required for Zymo RiboFree sequencing – was routinely achieved.
203 Although this threshold is reachable via deep-well extraction, optimizing magnetic bead protocols
204 significantly improved nucleic acid recovery (Table 2), enabling use of standard plate formats.
205 Using 600 µL of lysate, 500 ng RNA was obtained in 93% of samples, with a median RNA yield
206 of 1.5 µg.
207
208 We assessed transcript degradation during ambient-temperature storage by measuring the DI of
209 the 25th percentile of genes using DegNorm[26]. RNA degradation causes 3′ coverage bias in RNA-
210 seq data. The DI [26] quantifies this degradation at the gene level, with higher scores reflecting
211 greater 3′ bias. Based on sample collection and processing dates, samples spent an average of
212 6.7 ± 3.52 days in buffer. No significant change in 5′–3′ coverage bias (DI_25) between days 1
213 and 21 (Figure 2a), indicating stability at typical shipping conditions. We further assessed the
214 impact of menstrual flow rate on RNA quality. Flow rate had a strong effect on DI_25: participants
215 with slower flows (<1 grams/hr) had higher degradation, whereas faster flow rates (1–2 grams/hr
216 or >2 grams/hr) correlated with reduced degradation (p=0.002; cohen's f = 0.230 Figure 2b).
217 Extended collection times in slow-flow individuals may exacerbate degradation.
218
219 No seasonal effects on DI_25 were observed (Figure 2b). We did detect significantly lower overall
220 degradation in samples collected in the Midwest region of the United States (p = 0.023; cohen's f

221 = 0.127) (Figure 2d). While not statistically significant, samples from the Midwest also show an
222 increase in mean flow rate compared to other regions (Midwest mean= 1.423 g/hr; Other Region
223 mean = 1.149 g/hr; p = 0.090; cohen's f = 0.110). This could explain the decrease in DI_25 scores
224 for this region. A total of 11 kits were successfully sequenced at least three times by separate
225 technicians, showing a median coefficient of variation between replicates of 0.149 (supplemental
226 data).
227
228 From 600 µL lysate, we consistently recovered sufficient RNA and DNA for sequencing. RNA
229 remains stable for at least two weeks in buffer at ambient temperatures, showing minimal
230 transcript degradation (see Figure 2a,b) – making this system ideal for at-home collection. With
231 17 mL total lysate per tampon (equivalent volume to extract and sequence the sample 28 times),
232 ample material remains for molecular assays and biobanking. Collectively, we have biobanked
233 2,013 tampon-derived samples.
234
235 **DNA from tampon-collected menstrual effluence yields variant calls that are concordant**
236 **with those obtained from matched blood-based exome sequencing.**
237 At-home, longitudinal collection of menstrual effluence offers accessible prenatal and antenatal
238 screening, especially in gynecological deserts or where remote sampling enhances clinical care[28].
239 To assess concordance of single nucleotide variants (SNVs) between menstrual effluence and
240 venous blood, both sample types were collected from 12 participants and exome sequenced via
241 Labcorp's Inheritest.
242
243 Percentage of overlapping SNVs between blood and menstrual samples was high
244 (mean = 0.983 ± 0.0089), which is similar to other studies showing high concordance of SNVs
245 between different sample types from the same patient[29]. On average, menstrual effluence
246 detected 143 more SNVs than venous blood. Non-overlapping SNVs had lower coverage than

247 overlapping SNVs, likely explaining the difference (median coverage depth for overlapping
248 SNVs = 103 vs. non-overlapping SNVs = 40). Four participants carried pathogenic variants
249 detected in both sample types: GJB2:p.Gly12fs (hearing loss), CFTR:p.Ile507_Phe508delinsIle
250 (cystic fibrosis), CAPN3:p.Arg489Gln (limb-girdle muscular dystrophy), and HEXA:p.Arg499Hi
251 (Tay-Sachs), with allele frequencies ranging from 38% to 62% (Figure 3).
252
253 ***The transcriptomic profile of menstrual effluence represents a unique composite of***
254 ***uterine, vaginal, and immune-derived cells distinct from isolated reproductive tissues.***
255 To assess tissue similarity, we compared RNA expression profiles of menstrual effluence
256 collected via tampon (MB) and menstrual cup (MC) to GTEx data. Reproductive tissues (ovary,
257 vagina, fallopian tubes, cervix, uterus), whole blood, and small intestine (as outgroup) were
258 included. Spearman correlation was used to evaluate global similarity. Differential expression was
259 performed between menstrual effluence and GTEx whole blood samples to determine overlapping
260 genes between menstrual and reproductive tissues. The top 25 overexpressed genes in
261 menstrual effluence show some overlap with reproductive tissues in GTEx (Figure 4b),
262 demonstrating both shared and unique gene programs between the tissues. MB and MC samples
263 were highly correlated (Spearman's r = 0.97), with key differences in keratinized epithelium
264 expression (Supplemental Figure 1a), likely due to vaginal wall cell inclusion in tampon samples[19].
265 Reproductive tissues showed low correlation (r = 0.23–0.32), comparable to small intestine or
266 whole blood (r = 0.45; Figure 4a). This suggests that menstrual effluence shares only a limited
267 transcriptional overlap with reproductive tissue biopsies, similar to the non-reproductive tissues
268 included in the analysis. Differences in cycle phase and sequencing technology of GTEx data
269 may also contribute to this low correlation. The mixture of blood, uterine, and vaginal tissue could
270 represent shared gene programs between multiple tissue types leading to low correlations to any
271 one tissue.
272

Gene expression signatures in menstrual effluence vary according to user-reported hormonal use, flow rate, and cycle timing, enabling molecular phenotyping.

Endometrial gene expression provides valuable insight into menstrual physiology and molecular phenotypes, spanning objective metrics like flow rate (grams/hour) to subjective variables such as self-reported cycle day and flow type. To identify potential molecular correlates, we curated 89 endometrial-enriched genes from the Human Protein Atlas. Of these, 64 were detected in our sequencing data, with 30 genes showing JaneScore-normalized expression ≥2. Notable examples include canonical endometrial markers such as *PAEP*, *ESR1*, and several matrix metalloproteinases (*MMP10*, *MMP11*). The genes not present or at low expression may represent inherent differences between menstrual effluence and endometrium or be due to varying approaches in RNA sequencing.

Flow rate varies by birth control and subjective flow phenotype. Patients using any form of birth control exhibited reduced menstrual flow, as determined from 569 samples with reported data (Figure 5a). When flow rate was combined with spectrophotometric hemoglobin measurements at 550 nm, self-identified heavy bleeders (n = 83) showed significantly darker, more hemoglobin-rich effluence ($p < 0.0001$; cohen's $f=0.352$); Figure 5b). This single-tampon assay presents a scalable alternative to the burdensome alkaline hematin method, which requires collection of all products used over an entire cycle.

Genes enriched in the endometrium correlate with cycle day and flow type. Expression of *GNLY*, a broad-spectrum antimicrobial protein, varied significantly by cycle day ($p < 0.0001$; cohen's $f=0.394$; Figure 5c), indicating immune modulation across menstruation. Furthermore, self-reported flow heaviness (Heavy, Medium, Light, Spotting) was strongly associated with *PAEP* expression in tampon samples ($p < 0.0001$; cohen's $f= 0.469$; Figure 5d).

299 ***Menstrual effluence contains transcriptionally active microbial signatures that vary with***
300 ***menstrual day and may include clinically relevant pathogens.***
301 Menstrual samples show a time dependent dysbiosis in microbial transcription with an increase
302 in BV causing bacteria on days 2 and 3 of menstruation. RNA transcriptional activity is distinct
303 from the presence (relative abundance) of microbial DNA. We performed genus-level
304 metatranscriptomic analysis using Kraken2 on RNA reads. We identified high transcriptional
305 activity from several bacterial genera commonly associated with vaginal and uterine microbiota,
306 including *Prevotella*, *Gardnerella*, *Corynebacterium*, *Finegoldia*, and *Anaerococcus* (Figure 6a).
307 These genera are often implicated in microbial dysbiosis and reproductive tract infections.
308 *Lactobacillus* species – typically associated with a healthy reproductive tract – were found to
309 inversely correlate with the abundance of other bacterial taxa. In samples where *Lactobacillus*
310 activity was high, the activity of other bacteria was generally suppressed. However, many samples
311 exhibited low *Lactobacillus* levels (sum of all *Lactobacillus* species below 50% in 746 out of 1,135
312 sequences). alongside elevated expression of potentially pathogenic or opportunistic species.
313 Interestingly, total *Lactobacillus* transcriptional activity decreased significantly on menstrual days
314 2 and 3 (Figure 6b), suggesting a temporal shift in microbial composition during menstruation.
315 These findings present an opportunity to explore and understand typical microbial transitions
316 during a single menstrual cycle and map how vaginal microbiome returns to equilibrium after a
317 menstrual disruption.
318
319 **DISCUSSION**
320 This study presents a standardized, at-home tampon-based system for the collection and
321 stabilization of menstrual effluence, offering a scalable approach for molecular diagnostics and
322 research in women's health. The system preserves RNA and DNA for at least two weeks without
323 refrigeration, supporting applications such as genetic carrier screening, RNA and exome
324 sequencing, and microbial profiling. Its simplicity and suitability for at-home sampling help

325 overcome persistent barriers to diagnostic access, especially in underserved populations.
326 Through the NGJ platform, patients seeking to get pregnant could access their genetic screening
327 results and uterine microbiome insight from a single sample collected at home.
328
329 A key contribution of this work is the ability to maintain nucleic acid integrity in a biologically
330 complex, degradation-prone matrix. Menstrual effluence contains a heterogeneous mixture of
331 blood, endometrial tissue, vaginal secretions, and immune cells, which contribute to enzymatic
332 degradation. By limiting tampon wear to four hours, using chemically inert, low-absorbency cotton
333 tampons, and stabilizing samples in a high-performance buffer, we preserved high-quality RNA
334 and DNA for downstream molecular applications. Higher menstrual flow rates correlated with
335 improved RNA quality, likely due to greater blood content and reduced degradation time.
336 Post-collection experiments further underscored the importance of immediate stabilization, as
337 RNA integrity declined significantly in samples exposed to 37°C for just 30 minutes before
338 preservation (Supplementary Figure 1). These findings provide actionable insights for real-world
339 implementation of mail-in collection systems.
340
341 From a systems biology perspective, our findings highlight menstruation as a dynamic and
342 immunologically active window into reproductive health. Transcriptomic profiles varied across the
343 cycle and by hormonal use, with genes such as *PAEP*, *ESR1*, *GNLY*, and *MMP10* reflecting
344 hormonal withdrawal, immune activation, and tissue remodeling. These changes are difficult to
345 capture via biopsy or swabs, underscoring the value of menstrual effluence for temporal molecular
346 profiling that should be accounted for in research and clinical findings[30–32].
347
348 The high concordance between venous blood and menstrual effluence in exome sequencing
349 supports its use as a non-invasive alternative for carrier screening. Variants linked to conditions
350 such as cystic fibrosis and Tay-Sachs were concordantly detected in both sample types,

351 demonstrating that menstrual effluence can expand access to genomic testing.

352

353 Our system also links subjective menstrual experiences with objective molecular measurements.
354 Variables such as flow heaviness and cycle day correlated with RNA gene expression patterns,
355 suggesting tampon-derived metrics could serve as proxies for subjective reporting or hematin-
356 based methods in heavy menstrual bleeding classification.

357

358 Beyond transcriptomics, metatranscriptomic profiling revealed day-specific shifts in microbial
359 communities. Decreases in *Lactobacillus* and increases in *Gardnerella* and *Prevotella* during
360 menstruation suggest a transient dysbiosis. Coupling host transcriptional responses with
361 microbial activity enables nuanced assessment of conditions like bacterial vaginosis or chronic
362 endometritis, which affect a significant proportion of infertile individuals[33]. Immune activation
363 markers may help determine whether antibiotic treatment is warranted in asymptomatic cases[34,35].
364 Our system allows for this dual measurement in a single, non-invasive specimen. RNA
365 transcriptional profiles of the menstrual microbial community expand the potential of menstrual
366 effluence as a non-invasive monitoring tool for chronic infections, sexually transmitted infections,
367 or dysbiosis-associated conditions like pelvic inflammatory disease.

368

369 The reproducibility and standardization of this collection method also make it well-suited for
370 research at scale. By capturing molecular profiles tied to menstrual phenotypes, this platform can
371 enable the development of classifiers for endometriosis, fibroids, and other gynecologic
372 conditions. Future work will endeavor to utilize this system to better understand the molecular
373 characteristics of menstrual effluence and how variation in cycle data within patients and between
374 patients may influence normal or abnormal menstruation.

375

376 **CONCLUSION**

377 In conclusion, the development and validation of a standardized tampon-based system for
378 menstrual effluence collection marks a significant advancement in women's health diagnostics.
379 Our findings demonstrate that menstrual effluence, a sample previously considered suboptimal
380 for molecular analysis, can be preserved effectively for RNA and DNA extraction, enabling genetic
381 screening, molecular phenotyping, and pathogen surveillance. This system offers unique
382 opportunities for at-home, longitudinal monitoring of reproductive health, facilitating both clinical
383 care and research applications.
384
385 The ability to link menstrual biomarkers with clinical outcomes, such as genetic carrier status or
386 microbial dysbiosis, provides new avenues for early detection and personalized treatment
387 strategies. By providing reliable, reproducible molecular data across diverse menstrual phases
388 and bleeding phenotypes, this approach enhances the potential for diagnostic tools that address
389 the unique health needs of women. Future work will focus on refining the system's integration into
390 clinical practice, developing molecular classifiers for reproductive diseases like endometriosis,
391 and expanding the applications of menstrual effluence in broader health research.
392
393 **Conflicts of Interest**
394 Ridhi Tariyal, Stephen Gire, Xitong Li, and Claire Toth are or were employed by NextGen Jane,
395 Inc. which manufactures the tampon collection kit. The other authors did not report any potential
396 conflicts of interest.
397
398 **Funding Sources**
399 This work was funded in part through an SBIR FastTrack grant from NICHD. Unique Federal
400 Award Identification Number R44HD103159.
401
402 **Acknowledgements**

403 We would like to thank Stephen Palmer, Ruth Kulicke, Matt Stremlau, Ryan Phan, and Pardis
404 Sabeti for their helpful edits. We would like to thank the LabCorp team that helped coordinate
405 exome sequencing efforts: Marcia Eisenberg, Christina Smith, and Megann Vaughn. We would
406 like to thank Abhishek Jha and Yogesh Lakhotia for bioinformatic support. Margaret Eisen ,Julia
407 Carr and Aparna Kola coordinated all clinical collection efforts for this study. The analyses in this
408 paper were partly funded through an SBIR Fast Track grant with the National Institute of Child
409 Health and Disease *5R44HD103159.*

REFERENCES

1. Cromeens MG, Carey ET, Robinson WR, Knafl K, Thoyre S. Timing, delays and pathways to diagnosis of endometriosis: a scoping review protocol. BMJ Open. BMJ; 2021 Jun 24;11(6):e049390. PMCID: PMC8231065
2. Domar A, Vassena R, Dixon M, Costa M, Vegni E, Collura B, Markert M, Samuelsen C, Guiglotto J, Roitmann E, Boivin J. Barriers and factors associated with significant delays to initial consultation and treatment for infertile patients and partners of infertile patients. Reprod Biomed Online. Elsevier BV; 2021 Dec;43(6):1126–1136. PMID: 34756644
3. Fryer J, Mason-Jones AJ, Woodward A. Understanding diagnostic delay for endometriosis: a scoping review [Internet]. Obstetrics and Gynecology. medRxiv; 2024. Available from: https://www.medrxiv.org/content/10.1101/2024.01.08.24300988v1.full
4. Regensteiner JG, McNeil M, Faubion SS, Bairey-Merz CN, Gulati M, Joffe H, Redberg RF, Rosen SE, Reusch JE, Klein W. Barriers and solutions in women's health research and clinical care: a call to action. Lancet Reg Health Am. Elsevier; 2025 Apr;44:101037. PMCID: PMC11937288
5. Gonadotropin releasing hormone (GnRH) analogues. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID: 31643199
6. Saleh FL, Taylor HS. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F S Rep. Elsevier BV; 2023 Jun;4(2 Suppl):83–87. PMCID: PMC10201293
7. Madueke-Laveaux OS, Ciebiera M, Al-Hendy A. GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids. F S Rep. Elsevier BV; 2023 Jun;4(2 Suppl):46–50. PMCID: PMC10201292
8. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. Cancers (Basel). MDPI AG; 2020 Dec 11;12(12):3730. PMCID: PMC7763876
9. Pan C, Zhou M, Jian Y, Zeng Y, Wang M, Chen F. CA125: An increasingly promising biomarker of heart failure. Curr Pharm Des. Bentham Science Publishers Ltd.; 2021;27(37):3871–3880. PMID: 33461452
10. Al Mohamady M, Fattah GA, Elkattan E, Bayoumy R, Hamed DA. Correlation of serum CA-125 and progesterone levels with ultrasound markers in the prediction of pregnancy outcome in threatened miscarriage. Int J Fertil Steril. 2016 Jan;9(4):506–511. PMCID: PMC4793171
11. Chen Y, Pan M, Zuo Y, Yang B, Wang S. Research progress of CA125 in endometriosis: Teaching an old dog new tricks. gocm. BMJ; 2022 Dec;2(4):191–198.
12. Akinwunmi BO, Babic A, Vitonis AF, Cramer DW, Titus L, Tworoger SS, Terry KL. Chronic medical conditions and CA125 levels among women without ovarian cancer. Cancer Epidemiol Biomarkers Prev. American Association for Cancer Research (AACR); 2018 Dec;27(12):1483–1490. PMCID: PMC6279537
13. Rivo J, Page TF, Arrieta A, Amofah SA, McCann S, Kassaye H, Rodriguez A, Williams ML. The impact of comprehensive pre-visit preparation on patient engagement and quality of care in a population of underserved patients with diabetes: Evidence from the care management medical home center model. Popul Health Manag. Mary Ann Liebert Inc; 2016 Jun;19(3):171–177. PMID: 26440513
14. Vargas E, García-Moreno E, Aghajanova L, Salumets A, Horcajadas JA, Esteban FJ, Altmäe S. The mid-secretory endometrial transcriptomic landscape in endometriosis: a meta-analysis. Hum Reprod Open. Oxford University Press (OUP); 2022 Apr 4;2022(2):hoac016. PMCID: PMC9022214
15. Schwalie PC, Bafligil C, Russeil J, Zachara M, Biocanin M, Alpern D, Aasna E, Deplancke B, Canny G, Goncalves A. Single-cell characterization of menstrual fluid at homeostasis and in endometriosis [Internet]. medRxiv. 2024. p. 2024.05.06.24306766. Available from: https://www.medrxiv.org/content/10.1101/2024.05.06.24306766v1.full-text
16. Dobay A, Haas C, Fucile G, Downey N, Morrison HG, Kratzer A, Arora N. Microbiome-based body fluid identification of samples exposed to indoor conditions. Forensic Sci Int Genet. Elsevier BV; 2019 May;40:105–113. PMID: 30785061
17. Cindrova-Davies T, Zhao X, Elder K, Jones CJP, Moffett A, Burton GJ, Turco MY. Menstrual flow as a non-invasive source of endometrial organoids. Commun Biol. Springer Science and Business

Media LLC; 2021 Jun 17;4(1):651. PMCID: PMC8211845

18. van der Molen RG, Schutten JHF, van Cranenbroek B, ter Meer M, Donckers J, Scholten RR, van der Heijden OWH, Spaanderman MEA, Joosten I. Menstrual blood closely resembles the uterine immune micro-environment and is clearly distinct from peripheral blood. Hum Reprod. Oxford University Press (OUP); 2014 Feb;29(2):303–314. PMID: 24249743
19. Vlasac IM, Stolrow HG, Thayer ZM, Christensen BC, Rivera L. DNA-based cell typing in menstrual effluent identifies cell type variation by sample collection method: toward noninvasive biomarker development for women's health. Epigenetics. Informa UK Limited; 2025 Dec;20(1):2453275. PMID: 39825876
20. Marečková M, Garcia-Alonso L, Moullet M, Lorenzi V, Petryszak R, Sancho-Serra C, Oszlanczi A, Icoresi Mazzeo C, Wong FCK, Kelava I, Hoffman S, Krassowski M, Garbutt K, Gaitskell K, Yancheva S, Woon EV, Male V, Granne I, Hellner K, Mahbubani KT, Saeb-Parsy K, Lotfollahi M, Prigmore E, Southcombe J, Dragovic RA, Becker CM, Zondervan KT, Vento-Tormo R. An integrated single-cell reference atlas of the human endometrium. Nat Genet [Internet]. 2024 Aug 28; Available from: http://dx.doi.org/10.1038/s41588-024-01873-w PMID: 39198675
21. Demir AY, Demol H, Puype M, de Goeij AFPM, Dunselman GAJ, Herrler A, Evers JLH, Vandekerckhove J, Groothuis PG. Proteome analysis of human mesothelial cells during epithelial to mesenchymal transitions induced by shed menstrual effluent. Proteomics. Wiley Online Library; 2004 Sep 24;4(9):2608–2623. PMID: 15352236
22. Kamiyama S, Teruya Y, Nohara M, Kanazawa K. Impact of detection of bacterial endotoxin in menstrual effluent on the pregnancy rate in in vitro fertilization and embryo transfer. Fertil Steril. Elsevier BV; 2004 Oct;82(4):788–792. PMID: 15482745
23. Naseri S, Rosenberg-Hasson Y, Maecker HT, Avrutsky MI, Blumenthal PD. A cross-sectional study comparing the inflammatory profile of menstrual effluent vs. peripheral blood. Health Sci Rep. Wiley Online Library; 2023 Jan 5;6(1):e1038. PMCID: PMC9813904
24. Gursoy AY, Caglar GS, Kiseli M, Pabuccu E, Candar T, Demirtas S. CRP at early follicular phase of menstrual cycle can cause misinterpretation for cardiovascular risk assessment. Interv Med Appl Sci. Akademiai Kiado Zrt.; 2015 Dec;7(4):143–146. PMCID: PMC4701164
25. Handy AB, Greenfield SF, Yonkers KA, Payne LA. Psychiatric symptoms across the menstrual cycle in adult women: A comprehensive review. Harv Rev Psychiatry. Ovid Technologies (Wolters Kluwer Health); 2022;30(2):100–117. PMCID: PMC8906247
26. Xiong B, Yang Y, Fineis FR, Wang JP. DegNorm: normalization of generalized transcript degradation improves accuracy in RNA-seq analysis. Genome Biol. 2019 Apr 16;20(1):75. PMCID: PMC6466807
27. Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, Vedell PT, Barman P, Wang L, Weinshiboum R, Jen J, Huang H, Kohli M, Kocher JPA. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. Springer Science and Business Media LLC; 2016 Feb 3;17(1):58. PMCID: PMC4739097
28. Byström JW, Vikström L, Rosendal E, Gröning R, Gwon YD, Nilsson E, Sharma A, Espaillat A, Hanke L, McInerney G, Puhar A, Cava F, Karlsson Hedestam GB, Thunberg T, Monsen T, Elgh F, Evander M, Johansson AF, Överby AK, Ahlm C, Normark J, Forsell MN. At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. Euro Surveill [Internet]. European Centre for Disease Control and Prevention (ECDC); 2023 Mar;28(13). Available from: http://dx.doi.org/10.2807/1560-7917.ES.2023.28.13.2200432 PMCID: PMC10064644
29. Zhu Q, Hu Q, Shepherd L, Wang J, Wei L, Morrison CD, Conroy JM, Glenn ST, Davis W, Kwan ML, Ergas IJ, Roh JM, Kushi LH, Ambrosone CB, Liu S, Yao S. The impact of DNA input amount and DNA source on the performance of whole-exome sequencing in cancer epidemiology. Cancer Epidemiol Biomarkers Prev. American Association for Cancer Research (AACR); 2015 Aug;24(8):1207–1213. PMCID: PMC4526319
30. Schisterman EF, Mumford SL, Sjaarda LA. Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women. Epidemiol Rev. Oxford University Press (OUP); 2014;36(1):71–82. PMCID: PMC3873842
31. Lamon S, Le Carré J, Petito G, Duong HP, Luthi F, Hiam D, Léger B. The effect of the menstrual cycle on the circulating microRNA pool in human plasma: a pilot study. Hum Reprod. 2023 Jan 5;38(1):46–56. PMCID: PMC9825267

32. Rocks D, Cham H, Kundakovic M. Why the estrous cycle matters for neuroscience. Biol Sex Differ. 2022 Oct 28;13(1):62. PMCID: PMC9615204
33. Hmaidan S, Holt E, Finer Z, Session DR, Roach M. The use of endometrial culture for targeted treatment of endometritis in patients experiencing infertility and recurrent pregnancy loss. Fertil Steril. Elsevier BV; 2022 Oct;118(4):e208.
34. Muzny CA, Schwebke JR. Asymptomatic bacterial vaginosis: To treat or not to treat? Curr Infect Dis Rep [Internet]. Springer Science and Business Media LLC; 2020 Dec;22(12). Available from: http://dx.doi.org/10.1007/s11908-020-00740-z PMCID: PMC8015387
35. Ng BK, Chuah JN, Cheah FC, Mohamed Ismail NA, Tan GC, Wong KK, Lim PS. Maternal and fetal outcomes of pregnant women with bacterial vaginosis. Front Surg. 2023 Feb 13;10:1084867. PMCID: PMC9968788
36. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. Springer Science and Business Media LLC; 2010 Dec;28(12):1248–1250. PMID: 21139605
37. The human proteome in endometrium - The Human Protein Atlas [Internet]. [cited 2025 Apr 16]. Available from: https://www.proteinatlas.org/humanproteome/tissue/endometrium

538 **Table 1: Patient, Cycle, and Tampon level data collection summary**

A. Patient Level Data for 276 Patients	
Age	
<35	166
35-40	74
>40	36
Ethnicity	
Hipanic of Latino	33
Non-Hispanic	235
Other/NA	8
Race	
Asian	23
Black or African American	21
More than on race	21
White	207
American Indian or Alaska Native	1
Other/NA	3
Region of Collection	
Midwest	42
Northeast	46
South	91
West	97

B. Cycle Level Data for 365 Cycles	
Age	
<35	218
35-40	99
>40	48
Birth Control	
No birth control	287
Progestin	28
Estrogen	2
Estrogen and Progestin	41
Other	7
Bleeding Phenotype	
Heavy	170
Medium	154
Light	41

C. Tampon/kit level Data for 601 Tampons	
Season of Collection	
Spring	223
Summer	157
Autumn	135
Winter	86
Flow Type	
Heavy	294
Medium	183
Light	113
Spotting	11
Cycle day	
1	172
2	284
3	145

539 Data was collected at the **a.** patient level, as well as the **b.** cycle and **c.** tampon level. Each patient
540 may have multiple collections within a cycle, and between many monthly cycles. During this time
541 of collection, patients age, change birth control, or may change their bleeding phenotype. We
542 have collected data on these three hierarchical levels to reflect these changes. This dataset
543 includes 601 tampons collected in 365 monthly cycles from 276 participants.

544 **Table 2: Nucleic acid recovery statistics**

	Nucleic acid recover per 100ul sample lysate		
	number of extractions	**median ng RNA per 100ul lysate**	**average stdev between replicates**
		ng nucleic acid	
RNA - MagBead	508	251.67	28.43
RNA - Column	627	78.20	28.14
DNA - MagBead	12	80.80	NA

545 Total amount of nucleic acid (in nanograms) per 100ul of lysate was calculated by multiplying the
546 elution volume by the concentration of nucleic acid and then divided by the total volume of sample
547 lysate extracted. Data was calculated only on kits with at least 2 replicates between column-based
548 and magnetic bead-based extraction methods for RNA in order to calculate standard deviation of
549 extracted RNA at the kit level. DNA samples were not extracted in replicates and so standard
550 deviation was not calculated.

Figure 1: NextGen Jane tampon collection kit



NextGen Jane collection kit. **a.** Nitrile glove included for tampon removal. **b.** Included tampon with applicator. **c.** Cap that seals tampon in jar and releases preservative onto tampon. **d.** Basic phenotypic data about current collection is recorded on the inside flap of the box. These include the flow type of the tampon being collected, the day of the cycle, the date, time in and time out for collection, as well as a list of any medications taken during the collection **e.** Collection jar includes a sealed buffer cup with preservative. **f.** Biohazard bag with absorbent material for shipping. **g.** Tampon instructions for use. **h.** Front cover of the tampon collection instructions for use.

Figure 2: Degradation Index and sequence library size performance metrics



Sequencing metrics for monitoring degradation of RNA transcripts in menstrual collections. Higher DI scores correlate to more degraded samples. **a.** DI_25 score variance grouped by days sample left in buffer during transit show no significant changes by day (p = 0.107; cohen's f = 0.101). Samples were grouped days 1-3, 4-6, 7-9, and 10 or greater. **b.** DI_25 score plotted by rate of menstrual flow (grams of fluid collected divided by the hours of collections. Samples are bucketed in 0 to 1 grams of fluid lost per hour, 1 to 2 grams lost per hour, and over 2 grams lost per hour. There was a significant decrease in degradation as flow rate increased (p=0.002, cohen's f = 0.230) **c.** & **d.** DI_25 plotted by season (U.S) and by region (U.S.) the collection occurred. Midwest collected samples showed a lower mean DI_25 compared to other regions (p = 0.023; cohen's f = 0.127). Analysis was performed at the individual sequence level (n=1,135)

570 **Figure 3: SNV detection in DNA from matched whole blood and menstrual effluence**

571 **samples**

a.

Patient ID	SNVs detected in Venous	SNVs detected in Menstrual	Rate of Venous SNV confirmed in Menstrual
Patient 1	2642	2684	0.9637
Patient 2	2663	2787	0.9884
Patient 3	2713	3080	0.9849
Patient 4	2616	2704	0.9824
Patient 5	2656	2890	0.9857
Patient 6	2590	2608	0.9842
Patient 7	2641	2718	0.9909
Patient 8	2701	2926	0.9907
Patient 9	2804	3057	0.9904
Patient 10	3194	3214	0.9759
Patient 11	2603	2771	0.9697
Patient 12	2542	2648	0.9898
Average	**2697**	**2841**	**0.9830**
Standard Deviation	**170**	**193**	**0.0089**

b.



572

573 SNV summary statistics for the comparison of SNVs between 12 patients who were exome

574 sequenced using DNA extracted from menstrual effluence and from a venous blood draw. **a.**

575 Table summarizing the number of SNVs recorded in the venous blood and menstrual effluence,

576 and the rate of venous blood SNVs that were confirmed also in menstrual effluence. **b.** Four

577 patients with known pathogenic mutations in CFTR, GJB2, CAPN3 and HEXA were confirmed

578 present in both menstrual effluence and venous blood. Charts show mutation plotted against the

579 frequency of the SNV detected. Red points are menstrual and blue points are venous. 24 samples

580 from 12 participants were used in this analysis.

Figure 4: Sample type comparisons in menstrual effluence compared to other tissue types



Menstrual effluence gene expression global differences to other tissue types. **a.** Spearman correlation matrix of global RNA transcriptional activity in menstrual effluence (MB: tampon; MC: menstrual cup) compared to public datasets for small intestine, ovary, vagina, fallopian tube, cervix, uterus and blood. Red indicates a high level of transcriptional correlation between tissue types, while white and blue indicate a low level of correlation to other tissue types. 4,235 samples from GTeX and 218 samples from the NGJ dataset were used for this analysis. **b.** Top 25 differentially expressed genes between menstrual effluence and venous blood. Median gene values for 20 sequences from each GTeX tissue type were taken for comparison. Shared genes are grouped between reproductive tissue and menstrual (peach) vs menstrual samples with little to now expression in GTeX tissues (magenta). Expression differences in KRT13 between menstrual effluence collected in a menstrual cup or a tampon ($p < 0.0001$; cohen's $f = 2.072$). Analysis was done at the sequencing level (ESG) for 70 menstrual cup samples and 68 tampon samples.

596 **Figure 5: Flow rate and gene expression differences by sample collection characteristics**



597

598 Flow rate and hemoglobin content by birth control and heavy menstrual bleeding and the
599 differential expression of endometrial genes by cycle day. **a.** Flow rate calculated as grams of
600 fluid collected per hour plotted against patient use of hormonal birth control. Patients on any form
601 of hormonal birth control show lower flow rates ($p < 0.0001$; cohen's $f = 0.204$). Analysis was
602 performed at the kit level for 241 tampons with recorded flow rate. **b.** Flow rate multiplied by the
603 rfu (relative fluorescence units) spectrophotometer reading as a metric for hemoglobin within the
604 sample charted by whether patients self-report as heavy menstrual bleeders or normal menstrual
605 bleeders. Heavy bleeders show an increase in lost rate of hemoglobin per hour ($p < 0.0001$;
606 cohen's $f = 0.352$). Analysis was performed at the kit level for 241 tampons with recorded flow
607 rate. **c.** GNLY expression, an endometrium-enriched gene, by the day in the cycle (first cycle day
608 represents first day of bleeding), shows significant expression changes by cycle day ($p < 0.0001$;
609 cohen's $f = 0.394$). **d.** PAEP, another endometrium enriched gene charted by the day specific flow
610 type during the tampon collection ($p < 0.0001$; cohen's $f = 0.469$). Mean and Median values are
611 represented by a red "+" and "—", respectively. C and d analyses were performed at the sequence
612 level (ESG) for 1,135 samples.

613 **Figure 6: RNA transcriptional activity of key bacteria in menstrual effluence**



614

615 **a.** *L. crispatus*, which is one beneficial lactobacillus species in the vaginal cavity alongside BV
616 causing bacteria at the genus level. CPM counts per genus were summed before log2
617 transformation. Mean and Median values are represented by a "+" and "—", respectively. **b.**
618 Genus level *Lactobacillus* shows a significant decrease in transcriptional activity on day 2 and
619 day 3 of menstruation, compared to day 1 ($p < 0.0001$, cohen's $f = 0.171$). Analyses were
620 performed at the sequence level (ESG) for 1,135 samples.

621 **Supplementary Table 1: Sample filtering parameters**

622 Menstrual samples collected on cycle days 1-3 that had complete metadata for collection date,
623 bleeding phenotype, flow type, birth control, collection time and reproductive stage were included
624 in the analysis. Samples were further filtered by technical sequencing QC metrics including proper
625 strandedness of reads, ribosomal rRNA contamination and uniquely mapped reads.

All Samples	**1867**
Cycle day and Menstrual	**1600**
Cycle days 1-3	
Exclude vaginal only samples	
Missing Data (0, Not Recorded, or NA)	**1346**
Collection Date	
Bleeding Phenotype	
Flow type	
Birth Control	
Collection time	
Reproductive Stage	
Technical Filters	**1135**
Strandedness >0.8	
rRNA < 3%	
Uniquely mapped reads >8M	

634 **Supplemental Figure 1: Supplemental analyses on menstrual cups**



635

636 **a.** Expression differences in KRT13 between menstrual effluence collected in a menstrual cup or
637 a tampon ($p < 0.0001$; cohen's $f = 2.072$). Analysis was done at the sequencing level (ESG) for 70
638 menstrual cup samples and 68 tampon samples. **b.** Menstrual effluence collected in menstrual
639 cups was either directly put into preservation buffer after collection or incubated at 37oC for 30
640 minutes before preservation ($p=0.003$; cohen's $f = 0.606$). A total of 10 diva cups from 5
641 participants were used in this analysis.